10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT00885612
- Lead Sponsor
- AstraZeneca
- Brief Summary
10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 1114
Inclusion Criteria
- Early Breast Cancer patients
- Postmenopausal Status
- patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months
Exclusion Criteria
- Advanced Breast Cancer patients(stage iii, iv)
- Patients who are hard to be analysed by limitation of chart record according to investigators discretion
- patients who already have been registered in this study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment. 1 visit
- Secondary Outcome Measures
Name Time Method To describe 10-year CHD risk comparing to the historical data of 10-year cancer-specific mortality in breast cancer 1 Visit To analyse CHD management patterns according to defined 10-year CHD risk categories 1 Visit To describe correlation between concommitant medication(Anthracycline, Trasuzumab) and CHD risk 1 Visit
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link aromatase inhibitors to coronary heart disease risk in postmenopausal breast cancer patients?
How do treatment patterns with aromatase inhibitors compare to standard-of-care therapies in NCT00885612 for CHD risk mitigation?
Which biomarkers are associated with differential coronary heart disease risk in postmenopausal early breast cancer patients on aromatase inhibitors?
What adverse events related to cardiovascular health are observed in postmenopausal patients using AstraZeneca's aromatase inhibitors for breast cancer?
Are there combination therapies or alternative drug classes that improve CHD risk management in postmenopausal breast cancer patients compared to aromatase inhibitors?
Trial Locations
- Locations (1)
Research Site
🇰🇷Ulsan, Korea, Republic of
Research Site🇰🇷Ulsan, Korea, Republic of